CD19 and diffuse large B-cell lymphoma: Phase II clinical trial by Qu et al. tested the efficiency of tandem CD-19/CD22 dual-targeted CAR-T cell therapy in 33 adult patients with R/R DLBCL pretreated with DFC lymphodepletion chemotherapy (decitabine, fludarabine plus cyclophosphamide).